xl765
Small moleculeexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00485719)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma · Phase 2
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
- PI3-kinase class IINHIBITOR
PI3-kinase class I inhibitor
- Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) ↗
- Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) ↗
- Phosphoinositide 3-kinase regulatory subunit 5 (PIK3R5) ↗
- Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3) ↗
- PI3-kinase p85-alpha subunit
- PI3-kinase p110-delta subunit
- PI3-kinase p110-alpha subunit
- PI3-kinase p110-gamma subunit
- PI3-kinase p110-beta subunit
- PI3-kinase p85-beta subunit
- PI3-kinase p110-delta/p85-alpha
- PI3-kinase p110-alpha/p85-alpha
- PI3K p110 beta/p85 alpha
- PI3-kinase subunit gamma/Phosphoinositide 3-kinase regulatory subunit 5
- Phosphatidylinositol 3-kinase regulatory subunit beta/Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform
- PIK3CG/PIK3R1
- Phosphatidylinositol 3-kinase regulatory subunit gamma
Chemistry & pharmacology
Loading structure…
SMILES
CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21- Mol. weight
- 270.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545366 ↗
Also known as
- sar245409
- sar245409
- sar245409
- sar-245409
- sar-245409
- voxtalisib
- voxtalisib
- voxtalisib
- voxtalisib
- xl765
- xl765
- xl765
- xl765
- xl-765
- xl-765
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01936363 | Phase 2 | Sep 1, 2013 | Merck KGaA, Merck Serono, Sanofi |
| NCT01587040 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | Sanofi |
| NCT01596270 | Phase 1 | Jun 1, 2012 | Sanofi |
| NCT01410513 | Phase 1 | Dec 1, 2011 | Sanofi |
| NCT01403636 | Phase 2 | Oct 1, 2011 | Sanofi |
| NCT01390818 | Phase 1 | May 1, 2011 | Merck KGaA, Merck Serono, Sanofi |
| NCT01240460 | Phase 1 | Jan 1, 2011 | Sanofi |
| NCT01082068 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2010 | Sanofi |
| NCT00777699 | Phase 1 | Aug 1, 2008 | Sanofi |
| NCT00704080 | Phase 1 | Aug 1, 2008 | Sanofi |
| NCT00485719 | Phase 1 | Jun 1, 2007 | Sanofi |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 11 | 9 | 2 | 2007 |
| Merck KGaA | For profit | 2 | 0 | 2 | 2011 |
| Merck Serono | For profit | 2 | 2 | 2 | 2011 |
3 organizations
Page 1 / 1